Diabetic Retinopathy Treatment Market
Diabetes is a chronic disorder associated with defects in the secretion of insulin from the pancreas or hyperglycemia linked to insulin resistance which ultimately leads to long term multi-organ complications of eye, kidneys, nerves, blood vessels and heart. The most common and severe sight threatening complication of diabetes is Diabetic Retinopathy (DR) with some form of DR present in around 25-33% diabetic persons at any time.
Diabetes is a chronic disorder associated with defects in the secretion of insulin from the pancreas or hyperglycemia linked to insulin resistance which ultimately leads to long term multi-organ complications of eye, kidneys, nerves, blood vessels and heart. The most common and severe sight threatening complication of diabetes is Diabetic Retinopathy (DR) with some form of DR present in around 25-33% diabetic persons at any time.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Report Description<br />
However, a dearth of skilled ophthalmologist combined with poor primary infrastructure<br />
and lack of insurance facilities are restraining the growth of global diabetic retinopathy<br />
market.<br />
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1322<br />
<strong>Diabetic</strong> <strong>Retinopathy</strong> <strong>Treatment</strong> <strong>Market</strong>: Segmentation<br />
<strong>Diabetic</strong> <strong>Retinopathy</strong> <strong>Treatment</strong> market is classified on the basis of Indication, <strong>Treatment</strong><br />
type, end users and geography.<br />
Based on indication, the global diabetic retinopathy marketcan be segmented as follows:<br />
• Non-Proliferative <strong>Diabetic</strong> <strong>Retinopathy</strong> (NPDR)<br />
• Mild<br />
• Moderate<br />
• Severe<br />
• Proliferative <strong>Diabetic</strong> <strong>Retinopathy</strong> (PDR)<br />
Based on <strong>Treatment</strong> type, the global diabetic retinopathy marketcan be segmented as<br />
follows:<br />
• Anti-Vascular Endothelial Growth Factor (VEGF) drug
Change language